HERCEPTIN
TRASTUZUMAB
Public price
6.890,00 MAD
Reimbursement base
6.890,00 MAD
Active substance
TRASTUZUMAB
Reimbursable
What is this medicine?
A HER2-directed antibody and topoisomerase inhibitor conjugate.
Verified summary
TRASTUZUMAB, POUDRE POUR PERFUSION, 150 MG, 1 BOITE 1 FLACON
Common uses
Treatment of HER2-positive early breast cancer, HER2-positive metastatic breast cancer, HER2-low and HER2-ultralow metastatic breast cancer, and HER2-mutant unresectable or metastatic non-small cell lung cancer.
Class
HER2-directed antibody and topoisomerase inhibitor conjugate
Availability note
Reimbursable
Hospital price
6.681,00 MAD
Strength
150 MG
Form
POUDRE POUR PERFUSION
Presentation
1 BOITE 1 FLACON
Type
P
Therapeutic class
ANTINEOPLASIQUE CYTOTOXIQUE
This information is informational and must be confirmed by a pharmacist or doctor. Do not change medicine or dosage based only on this page.
Price history
Reference price recorded since 2017-12-18: 6.890,00 MAD
Available presentations and strengths
Medicines with the same active substance
HERTRAZ
150 MG · BOITE 1 FLACON DE POUDRE + 1 FLACON DE DE SOLVANT 10ML
3,32 MAD
HERZUMA
150 MG · BOITE DE 1 FLACON DE 20 ML
3,32 MAD
KANJINTI
150 MG · BOITE DE 1 FLACON
3,32 MAD
OGIVRI
150 MG · UNE BOITE DE 1 FLACON
3,32 MAD
TRAZUVA
150 MG · BOITE DE 1 FLACON
3,32 MAD
HERTRAZ
440 MG · BOITE 1 FLACON DE POUDRE + 2 FLACONS DE DE SOLVANT 10 ML
8,92 MAD
HERZUMA
440 MG · BOITE DE 1 FLACON DE POUDRE DE 50 ML ET 1 FLACON DE SOLVANT DE 20 ML
8,92 MAD
KANJINTI
420 MG · BOITE DE 1 FLACON
8,92 MAD
OGIVRI
420 MG · UNE BOITE DE 1 FLACON
8,92 MAD
TRAZUVA
440 MG · BOITE DE 1 FLACON DE POUDRE ET 1 FLACON DE SOLVANT
8,92 MAD
KADCYLA
100 MG · BOITE D'UN FLACON DE 15 ML
15,23 MAD
KADCYLA
160 MG · BOITE D'UN FLACON DE 20 ML
24,12 MAD